{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:54:55Z","timestamp":1765382095142,"version":"3.44.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000277","name":"DEFRA","doi-asserted-by":"publisher","award":["SE4109"],"award-info":[{"award-number":["SE4109"]}],"id":[{"id":"10.13039\/501100000277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research","doi-asserted-by":"crossref","award":["BBS\/E\/I\/00007033","BBS\/E\/I\/00007036","BBS\/E\/I\/00007037"],"award-info":[{"award-number":["BBS\/E\/I\/00007033","BBS\/E\/I\/00007036","BBS\/E\/I\/00007037"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research","doi-asserted-by":"crossref","award":["BBS\/E\/I\/00002536"],"award-info":[{"award-number":["BBS\/E\/I\/00002536"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.antiviral.2018.04.015","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T22:39:44Z","timestamp":1524004784000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host"],"prefix":"10.1016","volume":"154","author":[{"given":"Eva","family":"Calvo-Pinilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-4173","authenticated-orcid":false,"given":"Simon","family":"Gubbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-7277","authenticated-orcid":false,"given":"Javier","family":"Ortego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3453-8557","authenticated-orcid":false,"given":"Javier","family":"Castillo-Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.04.015_bib1","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib2","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.04.015_bib3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1099\/0022-1317-81-4-993","article-title":"Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries","volume":"81","author":"Bentley","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib4","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1016\/j.vaccine.2010.02.024","article-title":"Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth","volume":"28","author":"Bruder","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1006\/viro.1993.1537","article-title":"Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2","volume":"196","author":"Burrage","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.04.015_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.04.015_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.01.009","article-title":"Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge","volume":"116","author":"Calvo-Pinilla","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.015_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -\/- mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.04.015_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005997","article-title":"Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA)","volume":"4","author":"Chiam","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.04.015_bib10","series-title":"Infectious Diseases of Livestock","first-page":"1231","article-title":"African horse sickness","author":"Coetzer","year":"2004"},{"key":"10.1016\/j.antiviral.2018.04.015_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070197","article-title":"Ns1 is a key protein in the vaccine composition to protect Ifnar(-\/-) mice against infection with multiple serotypes of African horse sickness virus","volume":"8","author":"de la Poza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.04.015_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nm.1850","article-title":"Effective induction of high-titer antibodies by viral vector vaccines","volume":"14","author":"Draper","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.04.015_bib14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.copbio.2004.09.001","article-title":"Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?","volume":"15","author":"Drexler","year":"2004","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"El Garch","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vetimm.2008.02.002","article-title":"A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse","volume":"123","author":"El Garch","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib17","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib18","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.vaccine.2009.05.044","article-title":"Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus","volume":"27","author":"Guthrie","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0264-410X(94)90052-3","article-title":"Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine","volume":"12","author":"House","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib20","first-page":"89","article-title":"Inactivated and adjuvanted vaccine for the control of the African horse sickness virus serotype 9 infection: evaluation of efficacy in horses and Guinea-pig model","volume":"49","author":"Lelli","year":"2013","journal-title":"Vet. Ital."},{"issue":"44","key":"10.1016\/j.antiviral.2018.04.015_bib21","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1016\/j.vaccine.2017.04.005","article-title":"Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination","volume":"35","author":"Manning","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib22","doi-asserted-by":"crossref","first-page":"7858","DOI":"10.1128\/JVI.00517-12","article-title":"Structural insight into African horsesickness virus infection","volume":"86","author":"Manole","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/viro.1999.9680","article-title":"Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus","volume":"257","author":"Martinez-Torrecuadrada","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.04.015_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1051\/vetres:2004021","article-title":"African horse sickness","volume":"35","author":"Mellor","year":"2004","journal-title":"Vet. Res."},{"key":"10.1016\/j.antiviral.2018.04.015_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vetimm.2006.01.008","article-title":"Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination","volume":"111","author":"Minke","year":"2006","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2460\/ajvr.68.2.213","article-title":"Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge","volume":"68","author":"Minke","year":"2007","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.antiviral.2018.04.015_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181382","article-title":"Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA\/simian adenovirus\/MVA vaccine regimens","volume":"12","author":"Moyo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.04.015_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.vetimm.2012.01.016","article-title":"Virus-specific CD8(+) T-cells detected in PBMC from horses vaccinated against African horse sickness virus","volume":"146","author":"Pretorius","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.antiviral.2018.04.015_bib29","first-page":"139","article-title":"Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus","volume":"66","author":"Romito","year":"1999","journal-title":"Onderstepoort J. Vet. Res."},{"key":"10.1016\/j.antiviral.2018.04.015_bib30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1749-6632.1996.tb53539.x","article-title":"Multiple gene expression in baculovirus system. Third generation vaccines for bluetongue disease and African horsesickness disease","volume":"791","author":"Roy","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.antiviral.2018.04.015_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0147-9571(94)90046-9","article-title":"African horse sickness virus structure","volume":"17","author":"Roy","year":"1994","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.015_bib32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib33","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1016\/j.vaccine.2008.07.037","article-title":"Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals","volume":"26","author":"von Teichman","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib34","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3201\/eid2212.160718","article-title":"African horse sickness caused by genome reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004-2014","volume":"22","author":"Weyer","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.015_bib35","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0264-410X(97)00039-X","article-title":"Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus","volume":"15","author":"Yang","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.04.015_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coi.2015.06.006","article-title":"Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine","volume":"35","author":"Zhou","year":"2015","journal-title":"Curr. Opin. Immunol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:59Z","timestamp":1759062539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218301694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":36,"alternative-id":["S0166354218301694"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.015","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}